Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$24.91−2.21 (-8.15%)
Close on Nov 17, 2026Market cap $977.52MP/E –Yield –
Alto Neuroscience operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Alto Neuroscience's operating cash flow for the twelve months ending Sep 30, 2026 was -$79.12M. For fiscal 2025 it was -$51.77M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$51.77M | – |
| FY2024 | Dec 31, 2024 | -$47.42M | – |
| FY2023 | Dec 31, 2023 | -$33.45M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$20.76M | – |
| Q2 FY2026 | Jun 30, 2026 | -$19.76M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.09M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.52M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.69M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.52M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.52M | – |
See a number that looks wrong?